Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ines precision-engineered KL-4 surfactant technology with the capillary aerosol generator technology. This integrated drug device system potentially can be uniquely customized to address specific respiratory diseases in a broad range of patient populations. Discovery's lead neonatal program utilizing the Chrysalis technology is Aerosurf administered via nasal continuous positive airway pressure (nCPAP) to treat premature infants in the Neonatal Intensive Care Unit (NICU) with RDS. Discovery plans to initiate multiple Phase 2 clinical studies of Aerosurf utilizing the Chrysalis aerosolization technology in 2007.

Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, commented, "The ability to effectively deliver a less-invasive aerosolized surfactant could potentially redefine respiratory critical care medicine. Historical attempts to achieve this ambitious goal have been constrained by current technological limitations. These data support our approach in collaboration with our partners at Chrysalis to address these historical limitations."

DISCLAIMER: The Aerosurf pre-clinical study results discussed above cannot be interpreted to reflect whether the investigational integrated drug device system will be safe or effective in humans.

About BPD

BPD is associated with surfactant deficiency and is diagnosed when premature infants require mechanical ventilation or supplemental oxygen either at the 28th day of life or 36 weeks PMA. Premature babies are often born with a lack of natural lung surfactant and are unable to absorb sufficient oxygen, resulting in RDS. These infants often require endotracheal intubation to administer one of the currently available animal-derived surfactants (usually within the first hours of birth), and to provide respiratory support via mechanical ventilation. Unfortunately, many infants relapse following initial therapy and require reintubation and prolonged mechanical ventilation as well as s
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/31/2015)... 31, 2015 BioLight ... BLGTY) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, today announced that its ... identified several new genetic markers with high potential ... treated with bisphosphonate drugs and was able to ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... Chicago -based Rush University Medical ... activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor ... motor complete cervical spinal cord injury (SCI). This ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... PALO ALTO, Calif. , April 28 Jazz Pharmaceuticals, Inc. (Nasdaq: ... financial results on Wednesday, May 5, 2010 .  Jazz Pharmaceuticals will host ... well as to discuss financial results and guidance, on May 5, 2010 ... , , , ...
... April 28 The biopharma mega-mergers that grabbed headlines last year ... are now in the critical post-integration period and the acquiring companies are ... too early for final verdicts, but clearly one M&A issue that continues ... , , , ...
Cached Medicine Technology:Jazz Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 5, 2010 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 3
(Date:8/31/2015)... ... August 31, 2015 , ... The more hours young adults spend watching television ... and bigger waist circumference, a 15-year analysis by the University of Pittsburgh Graduate School ... years, indicating that young adulthood is an important time to intervene and promote less ...
(Date:8/31/2015)... ... August 31, 2015 , ... With baseball season in full swing, many fans ... dominate the sports world. Fans desire nothing more than to see their favorite team ... children, especially those who are too young to really understand what all the fuss ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now welcomes ... Ghasri is a graduate of the University of California, Los Angeles. He graduated summa ... the University of California, Irvine Medical School. As a nationally recognized Regents Scholar, Dr. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Month 2015 in September by sharing the facts about the role of heredity ... and BRCA2 genetic mutations because of Angelina Jolie Pitt’s decisions to have both ...
(Date:8/31/2015)... ... 31, 2015 , ... In preparation for this November’s National Family Caregivers Month, ... sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” The information ... a variety of home healthcare challenges, specifically as they relate to caring for the ...
Breaking Medicine News(10 mins):Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3
... nation is once again readying itself for losing an hour ... This is a shock not only to those of us ... levels of the economy, from the individual to the world. ... Economics, Cues for Timing and Coordination: Latitude, Letterman, and Longitude, ...
... Statement from Chuck,Mohan, executive director and ... reports of possible links between childhood vaccinations ... studies documenting that childhood,vaccinations cause or worsen ... research in this area. Mitochondrial diseases are ...
... Program Offers Millions in Potential Savings, DALLAS, ... millions of dollars annually through an innovative,initiative of ... and RxHub,LLC. The proprietary program helps ACS, healthcare ... commercial insurers., The new program enables pharmacies ...
... factor for knee repair surgery, study suggests , , THURSDAY, ... active on the basketball court and soccer field, and ... surgery just as easily as their younger counterparts. , ... women in their 50s and 60s did well after ...
... Donates Proceeds to Rainforest Foundation and Promotes Natural Cancer ... ... Under the Canopy(R), the,premier organic lifestyle brand, launches its cutting edge 2008 ... of Luxury Home Fashion Collection at Natural Products Expo West, Under ...
... No. 1 Among Health Care: Pharmacy and Other Services; No. 1 ... ... No. 3 for Innovation, FRANKLIN LAKES, N.J., March 6 ... position within the Health,Care: Pharmacy and Other Services sector on Fortune,s ...
Cached Medicine News:Health News:Early to bed early to rise ... depends on the TV schedule in your time zone 2Health News:Early to bed early to rise ... depends on the TV schedule in your time zone 3Health News:ACS Launches Medicaid Cost Savings Initiative 2Health News:ACS Launches Medicaid Cost Savings Initiative 3Health News:ACL Tears Worth Fixing in Seniors 2Health News:Under the Canopy(R) Turns a New Leaf With 2008 Spring Season 2Health News:Medco Tops Fortune's List of 'America's Most Admired' Companies in its Industry 2Health News:Medco Tops Fortune's List of 'America's Most Admired' Companies in its Industry 3
... sensitivity chart test face is the most widely ... test provides for four (4) rows of sine-wave ... ft (2.5 meters), these gratings test the spatial ... The CSV-1000E provides a full contrast sensitivity curve, ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Medicine Products: